The Parkinsons Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinsons disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinsons database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinsons Research.
Learn more about Who We Are.
All PPMI participants are encouraged to call in for our quarterly study update call, tomorrow at 12 pm EST. Dr. Daniel Weintraub will discuss the impact of PD on cognition. Dr. Weintraub’s talk will center around his recent publication of PPMI data in the journal PLoS One. You can read the full research article online.
The 21st International Congress of Parkinsons Disease and Movement Disorders (MDS) conference will take place next week, June 4-8, in Vancouver, Canada. PPMI leadership is happy to announce that several posters will feature PPMI data. We invite you to look for PPMI at this years meeting: Blue Ribbon Highlight: 840 Multiple modality biomarker prediction […]
Nearly 180 PPMI investigators, coordinators, study cores, patient advisory and steering committee members, sponsors, and industry partners from around the world met in New York City May 3-4, 2017 to share PPMI study and scientific updates and to discuss the future of the initiative. The annual meeting remains a critical component to the study. It […]
The Parkinsons Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]
In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMIs unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinsons disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]
